The Herald Bulletin of Madison County, Indiana has published a feature about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for the treatment of opioid addiction.Read More
Fortune.com has featured Titan Pharmaceuticals (NASDAQ:TTNP) and its ProNeura technology, calling it a “formidable new class of pharmaceutical implants.”Read More
Closely held Braeburn Pharmaceuticals appointed Michael Derkacz as president and CEO, succeeding Behshad Sheldon, who is stepping down from both posts and as a director, effective immediately, but will continue to serve as a consultant to Braeburn.Read More
Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine was featured in an article about new developments in managing opioid addiction that was published in the peer-reviewed journal, Drug, Design, Development and Therapy.Read More
The online version of Fortune magazine has produced an article about the digital health revolution that discusses the contribution of Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant as a maintenance treatment for opioid addiction.Read More
Titan Pharmaceuticals (NASDAQ:TTNP) and its marketing partner, closely-held Braeburn Pharmaceuticals, received a potential shot in the arm as the White House called for expanded access to treatment in the war on opioid addition.Read More
A patient using Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant containing buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction has documented his experience on Janaburson’s Blog.Read More
The CBS affiliate in Pittsburgh, KDKA-TV has produced a segment on the benefits of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine for the maintenance treatment of opioid addiction.Read More
Drug Deliver Business News has carried an article about Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant, the first marketed product to provide maintenance treatment for opioid addiction continuously for six months following a single administration procedure.Read More
Closely held Braeburn Pharmaceuticals announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System (HCPCS) code, or permanent J-code, for Probuphine, the first and only six-month buprenorphine implant for the maintenance treatment of opioid addiction.Read More
Titan Pharmaceuticals (NASDAQ:TTNP), in a move to boost its product development and commercialization experience in the U.S., Europe and Asia, named Scott Smith and Dr. Rajinder Kumar to its board.Read More
Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA.Read More
Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was named a gold award winner at the 13th annual Stevie Awards for Women in Business in the category of "Best New Product or Service of the Year."Read More
Katherine Beebe, executive VP and chief development officer of Titan Pharmaceuticals (NASDAQ:TTNP), was interviewed on Facebook Live yesterday in conjunction with the company ringing the closing bell at the exchange.
Dr. Beebe discussed Titan’s Probuphine implant, which was approved by the FDA earlier this year for the treatment of opioid addiction, and its sales and marketing partner, Braeburn Pharmaceuticals.Read More
New York’s WPIX-TV has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction.Read More
The United States Senate on Wednesday voted overwhelmingly to pass the Comprehensive Addiction and Recovery Act (CARA). The Senate vote follows a similar near-unanimous vote in the House of Representatives last week and will send the bill to the President for his signature.
The American Society of Addiction Medicine (ASAM) welcomed passage of the legislation and called on Congress to fulfill its commitment to fund CARA fully this year.Read More
The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine.
The move was part of several announced by the administration as part of an effort to stem the opioid abuse epidemic that is killing nearly 80 people from overdoses every day.Read More
The first 10 patients received treatment last week with Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine, following FDA approval on May 26.
ProbuphineProbuphine was developed using Titan’s long-term, continuous drug delivery platform, ProNeura, for the maintenance treatment of opioid dependence.Read More
Titan Pharmaceuticals (NASDAQ: TTNP) is presenting data today from four post hoc sensitivity analyses of the final Phase 3 trial of Probuphine at a poster session during The College on Problems of Drug Dependence 78th Annual Meeting in Palm Springs.
Probuphine is a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid dependence.Read More
Titan Pharmaceuticals (NASDAQ:TTNP) has received a $15-million milestone payment from development and commercialization partner, Braeburn Pharmaceuticals, following FDA approval of Probuphine, the first six-month maintenance treatment of opioid dependence.
Under terms of the licensing agreement, closely-held Braeburn will pay Titan tiered royalties on net sales in the U.S. and Canada at rates ranging from the mid-teens to low-twenties. In addition, Titan is eligible for up to $165-million in milestone payments based on achievement of certain annual sales targets.Read More